相关实验视频
Updated: Jul 6, 2025

11:21
Robotic Ablation of Atrial Fibrillation
Published on: May 29, 2015
19.7K
无线电频率导管切除用于肺高血压患者的心房
Aikai Zhang1, Lei Ding1, Hongda Zhang1
1Department of Cardiology, State Key Laboratory of Cardiovascular Disease, Cardiovascular Institute, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
ESC heart failure
|January 10, 2024
概括
射频导管切除 (RFCA) 在患有肺高血压 (PH) 和心房 (AFL) 的患者中有效地恢复了鼻节奏. 重复切除是安全的,但高肺动脉静脉压 (PASP) 和异常性肺动脉高血压 (IPAH) 预测死亡率.
科学领域:
- 心脏病学 心脏病学
- 电子生理学 电子生理学
- 肺高血压是什么意思 肺高血压
背景情况:
- 肺高血压 (PH) 患者的心房 (AFL) 存在独特的管理挑战.
- 射频导管切除 (RFCA) 是这种人群中AFL的潜在治疗选择.
研究的目的:
- 评估RFCA对PH患者的AFL的疗效和安全性.
- 在这个队列中确定影响RFCA后死亡率的因素.
主要方法:
- 追溯分析58名PH患者的AFL接受RFCA.
- 使用考克斯回归和ROC分析评估AFL复发,死亡率和预测因素.
主要成果:
- 在初始RFCA期间,成功恢复91.4%的患者的鼻节律.
- 在22名患者中发生了AFL复发;重复RFCA在维持鼻节律方面是安全有效的.
- 肺动脉静脉压 (PASP) 和异常性肺动脉高血压 (IPAH) 是所有原因死亡率的独立预测因素.
结论:
- 在PH患者中,RFCA是一种安全且可行的AFL治疗方法.
- AFL复发与全因死亡率没有相关性.
- 增加的PASP和IPAH与PH患者的死亡风险增加有关,这些患者在RFCA后患有AFL.
相关概念视频
Disturbances in Heart Rhythm
961
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
961
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
167
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
167

